Good afternoon and welcome to Markets Desk, your midday read on what's moving markets and why.
The biggest headline in pharma today belongs to Eli Lilly, whose next-generation weight loss injection retatrutide has cleared a pivotal obesity trial. The drug works through a distinct mechanism from existing GLP-one therapies, and these results put Lilly on a clear path toward a regulatory filing. Expect the market to reprice competitive dynamics across the entire obesity space on this news.
Turning to fixed income, bonds have been under pressure globally, and the story goes deeper than any single geopolitical flashpoint. Even if tensions around Iran ease, the structural forces driving yields higher — persistent deficits, sticky inflation expectations, and central bank balance sheet normalization — are not going away. Investors holding duration need to understand that the headwinds here are secular, not situational.
And in Germany, the DAX managed to recover from a weak open, finishing the session up half a percent, led by automobile, healthcare, and industrial names. That's notable given that German private sector activity actually contracted in the latest read, meaning buyers were looking past the data and finding value in beaten-down cyclicals. It's a confidence trade, and a fragile one at that.
That's the tape. Markets Desk, signing off the floor.
